Global Summit Hears Pledges To Cut Pandemic Vaccine Development Times

Cooperation Is Key To Tackling Health Threats

 
• By Ian Schofield

Is a 100-day timeline for developing vaccines against newly identified health threats a realistic proposition? Attendees at this week’s Global Pandemic Preparedness Summit certainly think so. Meanwhile, Moderna has said it will build its first African mRNA plant in Kenya, and has pledged “never” to enforce its vaccine patents in lower-income countries.

Business team connect pieces of gears. Teamwork, partnership and integration concept
Global cooperation is the key to tackling future health emergencies • Source: Alamy

Biotech and vaccine manufacturers, the Coalition for Epidemic Preparedness Innovations (CEPI) and the UK government have outlined the steps they plan to take to achieve the “100-Days Mission” – a pledge to reduce the time taken to develop new vaccines within 100 days of the identification of a new pathogen with epidemic or pandemic potential.

“Today, industry has stepped forward to commit its expertise and resources to achieving the 100 Days Mission, including by investing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 
• By Michael McCaughan

The FDA wants to ensure participants in clinical trials involving genetic engineering done in China understand what the agency sees as privacy and security risks. The agency also wants cell therapy processing done outside of “hostile” countries.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By Sue Sutter

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.